BioNTech SE  

Founded in 2008, BioNTech SE is a clinical-stage, NASDAQ listed, biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases. Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. The vertically integrated approach builds on in-house diagnostics (combining next generation sequencing, genomics, bioinformatics, machine learning and artificial intelligence), a multi-drug platform approach, off-the-shelf drugs and individualized therapies as well as comprehensive in-house manufacturing capabilities.